SCHEMBL3483405

SCHEMBL3483405

CCC(=O)C(=O)O.[KH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1514891 0.96 FFAR3 (0.53)
SCHEMBL15648054 0.96
SCHEMBL24128 0.96
SCHEMBL15355728 0.96
SCHEMBL7067003 0.93
Methyl Alcohol SCHEMBL910138 0.93
SCHEMBL5855078 0.93
SCHEMBL9342811 0.93
Water SCHEMBL1009160 0.93
Ammonia Solution, Strong SCHEMBL9342914 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683092-B2 Crystalline forms of antidiabetic compounds MERCK SHARP & DOHME CORP. (US) 2010-03-23 US disclosed
EP-1858844-A4 NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS MERCK & CO INC (US) 2009-04-22 EP disclosed
US-20080221198-A1 Novel Crystalline Forms of Antidiabetic Compounds MERCK SHARP & DOHME CORP. 2008-09-11 US disclosed
EP-1858844-A1 NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS Merck & Co., Inc. (US) 2007-11-28 EP disclosed
WO-2006099077-A1 NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS MERCK & CO., INC. (US) 2006-09-21 WO disclosed